Skip to main content

pulmonary arterial hypertension Archives

Cell-free hemoglobin in pulmonary hypertension

Mar. 6, 2023—Cell-free hemoglobin generated by the lungs may be a therapeutic target for treating pulmonary arterial hypertension, Vanderbilt researchers found.

Read more


Study suggests new threshold for diagnosing PAH

Aug. 13, 2020—Doctors diagnosing pulmonary arterial hypertension (PAH) — elevated pulmonary pressure due to an issue in the small vessels of the lung — rely on a hemodynamic threshold set in the early 1970s to determine whether patients would be candidates for pulmonary vasodilator therapy.

Read more


Mitochondrial mutations and disease

Feb. 22, 2018—New findings suggest that oxidative stress damages mitochondrial DNA, and they link this damage to a disease state.

Read more


Block estrogen to treat lung disease

Aug. 17, 2017—Based on findings from Vanderbilt investigators and others, clinical trials of estrogen inhibition for pulmonary arterial hypertension have recently been approved and funded by the National Institutes of Health.

Read more


Marrow cells’ role in pulmonary hypertension explored

Jul. 28, 2016—Cells from the bone marrow participate in the development of pulmonary arterial hypertension (PAH), and they can also protect against it, according to new findings from a team of Vanderbilt University Medical Center investigators.

Read more


Hypertension hiatus

Feb. 23, 2016—New findings offer a potential strategy for preventing heritable pulmonary arterial hypertension.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more